Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02624843 · ClinicalTrials.gov registry record · Phase 3
Bioequivalence Study for Benzyl Alcohol Lotion 5%.
A Phase 3 study, sponsored by Akorn.
- Completed
- Registry status
- Phase 3
- Development phase
- 239
- Enrollment target
NCT02624843: Completed Phase 3 study, sponsored by Akorn.
NCT02624843 is a Phase 3 study that has completed, run by Akorn. The registered enrollment target is 239 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02624843, a Phase 3 study, has completed, sponsored by Akorn.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 239 participants
- Enrollment target
Study Summary
To establish the therapeutic equivalence and safety of a generic Benzyl Alcohol Lotion 5% with Ulesfia Lotion 5% in eradication of head lice in the study subjects.
Primary Outcome
Successful elimination of infestation by active treatment \[Time frame: 22 + 2 days\]. No evidence of active head lice infestation 22 days after enrollment.
Interventions
- DRUG Placebo
- DRUG Benzyl Alcohol Lotion 5%
- DRUG Ulesfia (benzyl alcohol lotion) 5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2015-08 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
What the finished NCT02624843 record still lists
NCT02624843 is an interventional study that assigns participants to a tested intervention. The registered 239 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02624843 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02624843 about?
NCT02624843 is a clinical study titled "Bioequivalence Study for Benzyl Alcohol Lotion 5%.". To establish the therapeutic equivalence and safety of a generic Benzyl Alcohol Lotion 5% with Ulesfia Lotion 5% in eradication of head lice in the study subjects.
What is the current status of trial NCT02624843?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 239 participants. The study started on 2015-08. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02624843?
The interventions under investigation include: Placebo (DRUG), Benzyl Alcohol Lotion 5% (DRUG), Ulesfia (benzyl alcohol lotion) 5% (DRUG).
Who is sponsoring clinical trial NCT02624843?
This trial is sponsored by Akorn, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02624843's enrollment target sits among peer trials
239 1291st of 2000 higher than 710 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia